<DOC>
	<DOCNO>NCT00576693</DOCNO>
	<brief_summary>PRIMARY HYPOTHESIS : Compared intensive medical therapy alone , intracranial angioplasty stenting combine intensive medical therapy decrease risk primary endpoint 35 % mean follow-up two year high-risk patient patient 70 % - 99 % intracranial stenosis transient ischemic attack ( TIA ) stroke within 30 day prior enrollment ) symptomatic stenosis major intracranial artery . SUMMARY : The best treatment prevention another stroke TIA patient narrow one artery brain uncertain . A common treatment use anti-clotting medication prevent blood clot form narrowed vessel . There variety medicine use purpose . These medication usually take rest patient 's life . However , treatment use successfully together anti-clotting medication patient narrow blood vessel heart study blood vessel brain . This treatment call stenting . Recent research also indicate benefit prevention recur stroke Intensive Medical Therapy , define treat risk factor stroke like high blood pressure , elevate LDL ( low density lipids - `` bad '' form cholesterol ) diabetes . The purpose study compare safety effectiveness either Intensive Medical Therapy PLUS Stenting Intensive Medical Therapy ONLY prevent stroke , heart attack death . The study enroll patient 5 year period . Each participant involve study minimum 1 year maximum 3 year . Fifty different medical center United States part study . Both Clinical Coordinating Center Statistical Coordinating Center entire study locate Emory University .</brief_summary>
	<brief_title>Stenting v . Aggressive Medical Management Preventing Recurrent Stroke Intracranial Stenosis</brief_title>
	<detailed_description>This investigator initiate design Phase III multicenter trial patient TIA non-disabling stroke within 30 day prior enrollment cause 70 % - 99 % stenosis major intracranial artery ( MCA , carotid , vertebral , basilar ) randomize ( 1:1 ) approximately 50 site : intensive medical therapy alone ( aspirin 325 mg / day entire follow-up , clopidogrel 75mg per day 90 day enrollment unless cardiologist recommend continue clopidogrel beyond 90 day cardiac indication , aggressive risk factor management primarily target blood pressure &lt; 140 / 90 mm Hg ( &lt; 130 / 80 diabetic ) LDL &lt; 70 mg / dl ) OR intracranial angioplasty stenting use Gateway balloon Wingspan self-expanding nitinol stent ( future FDA approve iteration balloon , stent , delivery system ) plus intensive medical therapy ( aspirin 325 mg / day entire follow-up , clopidogrel 75mg per day 90 day enrollment unless cardiologist recommend continue clopidogrel beyond 90 day cardiac indication , aggressive risk factor management primarily target blood pressure &lt; 140 / 90 mm Hg ( &lt; 130 / 80 diabetic ) LDL &lt; 70 mg / dl ) . Risk factor management perform study neurologist site assist innovative , evidence-based , educational , lifestyle modification program ( INTERxVENT ) administer regularly schedule time patient throughout study . All patient enrol trial follow first following : 90 day primary endpoint , death , close-out visit trial , occur within window 60 day March 31 , 2012 30 day March 31 , 2013 . Patients die primary endpoint follow-up follow 2-4.5 year .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Transient ischemic attack ( TIA ) nonsevere stroke within 30 day enrollment attributed 7099 % stenosis major intracranial artery ( carotid artery , MCA stem ( M1 ) , vertebral artery , basilar artery ) • may diagnose byTranscranial Doppler ( TCD ) , Magnetic Resonance Angiogram ( MRA ) , compute tomography angiography ( CTA ) qualify angiogram perform part study protocol must confirm catheter angiography enrollment trial 2 . Modified Rankin score ≤ 3 3 . Target area stenosis intracranial artery normal diameter 2.00 mm 4.50 mm 4 . Target area stenosis less equal 14 mm length 5 . Age ≥ 30 year ≤ 80 year . • Patients 3049 year require meet least one additional criterion ( ivi ) provide table qualify study . This additional requirement increase likelihood symptomatic intracranial stenosis patient 3049 year atherosclerotic . i. insulin dependent diabetes least 15 year ii . least 2 follow atherosclerotic risk factor : hypertension ( BP &gt; 140/90 antihypertensive therapy ) ; dyslipidemia ( LDL &gt; 130 mg /dl HDL &lt; 40 mg/dl fast triglyceride &gt; 150 mg/dl lipid lower therapy ) ; smoke ; noninsulin dependent diabetes insulin dependent diabetes less 15 year duration ; family history following : myocardial infarction , coronary artery bypass , coronary angioplasty stenting , stroke , carotid endarterectomy stenting , peripheral vascular surgery parent sibling &lt; 55 year age men &lt; 65 woman time event ii . history follow : myocardial infarction , coronary artery bypass , coronary angioplasty stenting , carotid endarterectomy stenting , peripheral vascular surgery atherosclerotic disease iv . stenosis extracranial carotid vertebral artery , another intracranial artery , subclavian artery , coronary artery , iliac femoral artery , low upper extremity artery , mesenteric artery , renal artery document noninvasive vascular imaging catheter angiography consider atherosclerotic v. aortic arch atheroma document noninvasive vascular imaging catheter angiography vi . aortic aneurysm document noninvasive vascular imaging catheter angiography consider atherosclerotic 6 . Negative pregnancy test female menses last 18 month 7 . Patient willing able return followup visit require protocol 8 . Patient available phone 9 . Patient understands purpose requirement study , make him/herself understood , provide informed consent EXCLUSION CRITERIA 1 . Tandem extracranial intracranial stenosis ( 70 % 99 % ) occlusion proximal distal target intracranial lesion ( NOTE : exception allow occlusion involve single vertebral artery proximal symptomatic basilar artery stenosis contralateral vertebral artery supply basilar artery ) 2 . Bilateral intracranial vertebral artery stenosis 70 % 99 % uncertainty artery symptomatic ( e.g . patient pontine , midbrain , temporal occipital symptom ) 3 . Stenting , angioplasty , endarterectomy extracranial ( carotid vertebral artery ) intracranial artery within 30 day prior expect enrollment date 4 . Previous treatment target lesion stent , angioplasty , mechanical device , plan perform stag angioplasty follow stenting target lesion 5 . Plan perform concomitant angioplasty stenting extracranial vessel tandem intracranial stenosis 6 . Presence intraluminal thrombus proximal target lesion 7 . Any aneurysm proximal distal stenotic intracranial artery 8 . Intracranial tumor ( except meningioma ) intracranial vascular malformation 9 . CT angiographic evidence severe calcification target lesion 10 . Thrombolytic therapy within 24 hour prior enrollment 11 . Progressive neurological sign within 24 hour prior enrollment 12 . Brain infarct within previous 30 day enrollment sufficient size ( &gt; 5 cm ) risk hemorrhagic conversion stenting 13 . Any hemorrhagic infarct within 14 day prior enrollment 14 . Any hemorrhagic infarct within 15 30 day associate mass effect 15 . Any history primary intracerebral ( parenchymal ) hemorrhage ( ICH ) 16 . Any intracranial hemorrhage ( subarachnoid , subdural , epidural ) within 30 day 17 . Any untreated chronic subdural hematoma great 5 mm thickness 18 . Intracranial arterial stenosis due arterial dissection , Moya Moya disease ; know vasculitic disease ; herpes zoster , varicella zoster viral vasculopathy ; neurosyphilis ; intracranial infection ; intracranial stenosis associate Cerebrospinal fluid ( CSF ) pleocytosis ; radiation induce vasculopathy ; fibromuscular dysplasia ; sickle cell disease ; neurofibromatosis ; benign angiopathy central nervous system ; postpartum angiopathy ; suspect vasospastic process , suspect recanalized embolus 19 . Presence follow unequivocal cardiac source embolism : chronic paroxysmal atrial fibrillation , mitral stenosis , mechanical valve , endocarditis , intracardiac clot vegetation , myocardial infarction within three month , dilate cardiomyopathy , leave atrial spontaneous echo contrast , ejection fraction le 30 % 20 . Known allergy contraindication aspirin , clopidogrel , heparin , nitinol , local general anesthesia 21 . History lifethreatening allergy contrast dye . If life threaten effectively pretreated , patient enrol physician 's discretion 22 . Active peptic ulcer disease , major systemic hemorrhage within 30 day , active bleeding diathesis , platelet &lt; 100,000 , hematocrit &lt; 30 , International normalize ratio ( INR ) &gt; 1.5 , clot factor abnormality increase risk bleeding , current alcohol substance abuse , uncontrolled severe hypertension ( systolic pressure &gt; 180 mm Hg diastolic pressure &gt; 115 mm Hg ) , severe liver impairment Aspartate Transaminase ( AST ) Alanine transaminase ( ALT ) &gt; 3 x normal , cirrhosis , creatinine &gt; 3.0 ( unless dialysis ) 23 . Major surgery ( include open femoral , aortic , carotid surgery ) within previous 30 day plan next 90 day enrollment 24 . Indication warfarin heparin beyond enrollment ( NOTE : exception allow use systemic heparin stenting procedure subcutaneous heparin deep vein thrombosis ( DVT ) prophylaxis hospitalize ) 25 . Severe neurological deficit render patient incapable living independently 26 . Dementia psychiatric problem prevents patient follow outpatient program reliably 27 . Comorbid condition may limit survival less 3 year 28 . Pregnancy childbearing potential unwilling use contraception duration study 29 . Enrollment another study would conflict current study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>ischemic stroke</keyword>
	<keyword>intracranial stenting</keyword>
	<keyword>vascular risk factor management</keyword>
</DOC>